期刊
INTERNATIONAL PSYCHOGERIATRICS
卷 27, 期 1, 页码 7-17出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1041610214001963
关键词
Alzheimer's disease; agitation; cognitive impairment; aggression; International Psychogeriatric Association; Food and Drug Administration; clinical trials; intervention; epidemiology
资金
- Otsuka and Avanir Pharmaceutricals
- Eli Lilly
- Associated Jewish Federation of Baltimore
- Weinberg Foundation
- Forest
- GlaxoSmithKline
- Eisai
- Pfizer
- Astra-Zeneca
- Lilly
- Ortho-McNeil
- Bristol-Myers
- Novartis
- National Football League
- Elan
- Functional Neuromodulation
- Takeda Global Research and Development Center
- Genentech
- Merck
- Accera
- Avanir
- F. Hoffmann-La Roche
- Baxter
- Wyeth
- Janssen Alzheimer Initiative
- Genentech/Roche
- Toyama
- Bayer
- MerckSerono
- Mertz
- Teva
- National Institute of Mental Health
- American Psychiatric Press
Background: Agitation is common across neuropsychiatric disorders and contributes to disability, institutionalization, and diminished quality of life for patients and their caregivers. There is no consensus definition of agitation and no widespread agreement on what elements should be included in the syndrome. The International Psychogeriatric Association formed an Agitation Definition Work Group (ADWG) to develop a provisional consensus definition of agitation in patients with cognitive disorders that can be applied in epidemiologic, non-interventional clinical, pharmacologic, non-pharmacologic interventional, and neurobiological studies. A consensus definition will facilitate communication and cross-study comparison and may have regulatory applications in drug development programs. Methods: The ADWG developed a transparent process using a combination of electronic, face-to-face, and survey-based strategies to develop a consensus based on agreement of a majority of participants. Nine-hundred twenty-eight respondents participated in the different phases of the process. Results: Agitation was defined broadly as: (1) occurring in patients with a cognitive impairment or dementia syndrome; (2) exhibiting behavior consistent with emotional distress; (3) manifesting excessive motor activity, verbal aggression, or physical aggression; and (4) evidencing behaviors that cause excess disability and are not solely attributable to another disorder (psychiatric, medical, or substance-related). A majority of the respondents rated all surveyed elements of the definition as strongly agree or somewhat agree (68-88% across elements). A majority of the respondents agreed that the definition is appropriate for clinical and research applications. Conclusions: A provisional consensus definition of agitation has been developed. This definition can be used to advance interventional and non-interventional research of agitation in patients with cognitive impairment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据